| |
Tuesday, May 20th |
|
7:00am-8:00am |
ISPOR Institutional
Council Breakfast (Private) |
|
7:00am-8:00am |
Breakfast
with the Experts |
 |
|
|
- Robert DeMarinis PhD, Assistant Vice
President-Global Health Outcomes Assessment, Wyeth-Ayerst Research,
Philadelphia, PA, USA
- Bryan Luce PhD, MBA, Senior Research
Leader & CEO, MEDTAP International, Bethesda, MD, USA
- George Torrance PhD, Professor
Emeritus, McMaster University, Burlington, ON, Canada
- Andrew Briggs PhD, Health Economics
Research Centre, Institute of Health Sciences, Oxford University,
Headington, Oxford, UK
|
|
8:00am-9:30am |
Contributed Podium Presentations |
|
|
| |
CARDIOVASCULAR DISEASE II |
| |
Moderator: Jon
Clouse RPh, MS, Executive Vice President, Ingenix, Eden Prairie,
MN, USA |
|
CV5 |
THE COST OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
FROM A STATE MEDICAID PROGRAM PERSPECTIVE
Marton J1, Boulanger L2, Menzin J2, Friedman M2, Dixon D2,
Wilson J1, 1Pfizer Inc, New York, NY, USA; 2Boston Health Economics,
Inc, Waltham, MA, USA |
|
CV6 |
NONCONFORMANCE WITH NCEP-ATP III RECOMMENDATION ON
LIPID/LIPOPROTEIN MEASUREMENT AT BASELINE: A RISK FACTOR FOR EMERGENCY
OR HOSPITALIZATION?
Yu AP1, Nichol MB2, 1USC School of Pharmacy, Los Angeles, CA,
USA; 2University of Southern California, Los Angeles, CA, USA |
|
CV7 |
COST-EFFECTIVENESS OF CLOPIDOGREL IN PATIENTS WITH
ISCHEMIC STROKE, MYOCARDIAL INFARCTION, OR PERIPHERAL ARTERIAL DISEASE
Delea TE1, Edelsberg JS1, Richardson E2, Singer DE3, Oster G1,
1Policy Analysis Inc. (PAI), Brookline, MA, USA; 2Harvard School of
Public Health, Boston, MA, USA; 3Harvard Medical School, Boston, MA, USA
|
|
CV8 |
CURRENT PATTERNS OF CARE AND TREATMENT COSTS
ASSOCIATED WITH VENOUS THROMBOEMBOLIC DISEASE
Bullano MF1, Hauch O2, Reynolds M2, Wygant G2, Drury CJ1, Willey
VJ1, 1Health Core, Newark, DE, USA; 2AstraZeneca, L.P, Wayne, PA, USA
|
|
|
MENTAL
HEALTH |
|
|
Moderator: William
R. Lenderking, PhD, Director, Outcomes Research, Pfizer Inc.,
Groton, CT, USA |
|
MH1 |
GENDER VARIATION IN QUALITY OF PHARMACOLOGIC CARE
OF CHILDREN DIAGNOSED WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER
(ADHD)
Sarawate CA1, Hankin C2, 1University of Illinois at Chicago,
Chicago, IL, USA; 2McNeil Consumer and Specialty Pharmaceuticals, Fort
Washington, PA, USA |
|
MH2 |
THE RELATIONSHIP OF ASTHMA AND GENERALIZED ANXIETY
DISORDER IN ADULTS
Marks AS, Kassulke JP, Allemand AM, Patel H, Caremark, Inc,
Northbrook, IL, USA |
|
MH3 |
EVALUATING THE ECONOMIC CONSEQUENCES OF EARLY SSRI
DROP-OUTS IN DEPRESSION
Eaddy M1, Sheehan D2, Sullivan L3, 1Applied Health Outcomes,
Tampa, FL, USA; 2University of South Florida, Tampa, FL, USA; 3State of
Tennessee, Nashville, TN, USA |
|
MH4 |
DRUG UTILIZATION ANALYSIS OF THE SSRI CLASS IN A
MEDICAID HMO: THE FLUOXETINE EXPERIENCE
Belazi D, Tegenu M, Keystone Mercy Health Plan, Philadelphia, PA,
USA |
|
|
NEUROLOGICAL DISEASES/DISORDERS |
|
|
Moderator:
Peter Neumann ScD, Assistant Professor of Policy & Decision
Sciences, Harvard School of Public Health, Boston, MA, USA |
|
ND1 |
COST-EFFECTIVENESS OF TOPIRAMATE AS ADJUNCTIVE
TREATMENT IN REFRACTORY EPILEPSY – A PROBABILISTIC ASSESSMENT OF
TREATMENT STRATEGIES
Remak E1, Hutton J2, Price M3, Peeters K4, Adriaenssen I4,
1MEDTAP International, Inc, Budapest, Hungary; 2MEDTAP International,
London, UK; 3Janssen-Cilag, High Wycombe, Bucks, UK; 4Johnson & Johnson
Pharmaceutical Services, Beerse, Belgium |
|
ND2 |
AN ESTIMATE OF THE DIRECT COSTS OF MIGRAINE IN THE
UNITED STATES USING THE MEDICAL EXPENDITURE PANEL SURVEY
Mychaskiw MA, Sankaranarayanan J, Purdue University, West
Lafayette, IN, USA |
|
ND3 |
ECONOMIC ANALYSIS OF ACUTE MIGRAINE THERAPY
UTILIZATION WITHIN THE WISCONSIN STATE MEDICAID POPULATION
Conner C1, Cherayil G2, 1Pfizer Inc, Milwaukee, WI, USA; 2Pfizer
Inc, Brookfield, WI, USA |
|
ND4 |
ARE ELDERLY PATIENTS RECEIVING APPROPRIATE
ANTIEPILEPTIC DRUGS?
Pugh MJV1, Cramer JA2, Knoefel JA3, Charbonneau A4, Berlowitz D4, 1VA
New England/Bedford VAMC, Bedford, MA, USA; 2Yale University, New Haven,
CT, USA; 3University of New Mexico, Albuquerque, NM, USA; 4Center for
Health Quality, Outcomes and Economic Research, VA, Bedford, MA, USA
|
|
|
EMPLOYER PERSPECTIVES |
|
|
Moderator: Pete
Fullerton PhD, Professor (Affiliate), UW Pharmaceutical Outcomes
Research and Policy Program, Seattle, Washington, USA |
|
EP1 |
THE IMPACT OF AN ALLERGY MANAGEMENT PROGRAM ON
LOST PRODUCTIVE TIME AT WORK
Maurer R1, Armstrong DS2, 1St. Joseph Heritage Healthcare, La
Mirada, CA, USA; 2Integrated Therapeutics Group, La Verne, CA, USA
|
|
EP2 |
COST ANALYSIS OF HEPATITIS C VIRUS (HCV)
INFECTION: AN EMPLOYER’S PERSPECTIVE
Duh MS1, Moyneur É2, Van Audenrode M3, Mody SH4, Piech CT4,
1Analysis Group/Economics, Boston, MA, USA; 2Analysis Group/Economics,
Montreal, QC, Canada; 3Université Laval, Québec, QC, Canada; 4Ortho
Biotech Products, LP, Bridgewater, NJ, USA |
|
EP3 |
WORK LOSS AND HEALTHCARE UTILIZATION AMONG U.S.
EMPLOYEES WITH CHRONIC NON-CANCER PAIN
Pizzi LT1, Carter CT2, Johnson NE3, Howell JB1,
Vallow SM2, Frank ED1, 1Thomas Jefferson University, Philadelphia, PA,
USA; 2Janssen Pharmaceutica, Titusville, NJ, USA; 3Outcomes Research &
Design, Inc, Spring, TX, USA |
|
EP4 |
ALLERGY PREVALENCE, COST, AND PRODUCTIVITY LOSS IN
AN INSURED EMPLOYEE POPULATION
Kleinman N1, Muchmore L1, Gardner H1, Borden S2, 1Options
& Choices, Inc, Cheyenne, WY, USA; 2Integrity Consulting, LLC, Concord,
MA, USA |
|
9:30AM-10:15AM |
Break, Exhibits, Contributed
Poster Presentations (Session II) |
|
|
| |
Break sponsored by NOVARTIS |
|
10:00AM-12:00PM |
Second Plenary Session
|
|
|
| |
Introductions:
Peter Davey MD, FRCP, 2002-2 003 ISPOR
President and Head of Pharmacoeconomics, University of Dundee, Dundee,
Scotland, UK |
| 10:00AM-10:10AM |
PhRMA Foundation 2003 Awards
in Health Outcomes |
|
|
| |
Presented by: Del
Persinger, President and CEO, Pharmaceutical Research
Manufacturers Association (PhRMA)
2003 Research Starter Grants in Health Outcomes
This award offers $30,000 per year for up to two years. The following
individuals will receive the award:
Tawny L. Bettinger PharmD, Assistant
Professor, University of Texas at Austin, Department of Pharmacy
Practice, Austin, Texas, USA – 1 Year
Amy Barton Pai PharmD, Assistant
Professor, University of New Mexico, College of Pharmacy, Albuquerque,
New Mexico, USA – 2 Years
Eve Wittenberg PhD, MPP, Senior
Scientist, MGH Institute for Technology Assessment, Instructor, Harvard
Medical School, Department of Radiology, Boston, Massachusetts, USA – 2
Years
2003 Pre Doctoral Fellowship in
Health Outcomes
This award offers $20,000 per year for up to two years. The following
individual will receive the award:
Joette M. Gdovin, University of
South Carolina, Department of Health Administration, Columbia, South
Carolina, USA
– 1 Year
2003 Post Doctoral Fellowship in Health Outcomes
The award offers $40,000 per year for up to two years. The following
individual has been selected to receive the award:
Brian L. Erstad PharmD, University
of Arizona, Department of Pharmacy Practice & Science, Tucson, AZ, USA –
1 Year
|
|
10:10am-10:25am |
Incoming Presidential
Address |
|
|
|
Sean Sullivan PhD, Incoming
ISPOR President and Professor, University of Washington, Seattle,
Washington, USA
|
|
10:25am-10:35am |
ISPOR Research Excellence
Awards |
|
|
|
Presented by: Newell
McElwee PharmD, MSPH, Chair, ISPOR Awards Committee and Group
Director, Outcomes Research, Pfizer Inc., New York, NY, USA
ISPOR Research Excellence Award
For Methodology Excellence
Awardee:
Jeffrey S. Hoch PhD, Assistant Professor of Health Economics,
Department of Epidemiology and Biostatistics, The University of Western
Ontario, London, Ontario, Canada
|
| 10:35am-12:00pm |
Use of Outcomes Research
Data in Assuring Patient Safety and Quality of Care |
|
|
|
12:00pm-1:00pm |
Lunch, Exhibits, Contributed
Poster Presentations (Session II) |
|
Lunch sponsored by AEGISnet |
|
|
|
1:00pm-2:00pm |
Issues Panels (4 Sessions) |
|
|
|
Cost-effectiveness ratios and net
monetary benefits: What’s gained and lost by their use?
Chair: Joseph Heyse PhD, Executive
Director, Biostatistics & Research Decision Sciences, Merck Research
Laboratories, West Point, PA, USA
Panelist: Steve Teutsch MD, MPH,
Executive Director, Merck and Company, West Point, PA, USA;
Eugene M Laska, PhD, Statistical Sciences
and Epidemiology Division, The Nathan S. Kline Institute for Psychiatric
Research, Orangeburg, NY, USA.
The purpose of economic evaluation using
cost-effectiveness analysis is to maximize the health effects obtained
for a given budget. Evaluations based on incremental cost-effectiveness
ratios have traditionally been a popular method of analysis. The use of
net monetary benefits has recently gained in popularity because it is
potentially more amenable to statistical analysis. The purpose of the
issues panel is to describe the relationship between cost-effectiveness
ratios and net monetary benefits, and to discuss important properties
for their application in health care decision making.
Transforming cost data: When is it appropriate?
Chair: Daniel Polsky PhD, Research
Associate Professor, University of Pennsylvania, Philadelphia, PA, USA
Panelist: Willard Manning, Professor,
University of Chicago, Chicago, IL, USA; Professor
Anthony O'Hagan PhD, Department of Probability and Statistics,
University of Sheffield, Sheffield, UK
How should the mean cost of treatment be estimated? When is the log
transformation the best way to handle skewed cost data? What
alternatives should be considered?
Risk Management: Looking for signals and targeting interventions
Chairs: Louis Morris PhD, President,
Louis A. Morris & Associates, Dix Hills, NY, USA;
Eva Lydick PhD, Director of Epidemiology, AstraZeneca Inc,
Wilmington, DE, USA
Panelists: John Urquhart, MD, FRCPE,
Professor of Pharmacoepidemiology, Maastricht University, Maastricht NL;
Judith Jones MD, PhD, President and CEO,
The Degge Group, Arlington, VA, USA
Outcomes research may
have an important, yet unrecognized, role in product safety and risk
management. This session will explore the use of outcomes research to
aid in reviewing the safety and approvality of prescription drugs.
Certain outcome measures may directly demonstrate the merits of product
benefits better than traditional clinical measures. These outcome
measures also may make risks and benefits of pharmaceuticals more
directly comparable and may make it easier for regulators to make
decisions about product approval. Outcomes research may also be used to
evaluate the effects of risk management plan implementation. By focusing
on outcomes of value to patients, the underlying influence of risk
management plans may be assessed. The panel will explore how outcomes
research may be useful in these various phases of product approval and
risk management.
Developing AMCP Format for Formulary Submission: What are the Issues?
Chair: Talat Ashraf MD, MS, Global
Director, Abbott Laboratories, Abbott Park, IL, USA
Panelist:
Kevin Schulman MD, Professor of Medicine
and Business Administration, Director, The Center for Clinical and
Genetic Economics, Duke Clinical Research Institute, Durham, NC, USA;
Joseph
DiCesare RPh, MPH, Executive Director, Health Economics and Outcomes
Research, Novartis Pharmaceuticals, East Hanover, NJ, USA;
Brenda Motheral RPh, PhD, Vice President,
Outcomes Research, Express Scripts, Maryland Heights, MO,USA.
This panel will discuss
important issues pertaining to the AMCP format for formularly
submission. The issues will be discussed from the perspective of pharmaceutical
companies, academia and managed care organization.
|
|
2:00pm-2:15pm |
Break |
|
Break sponsored by NOVARTIS |
|
|
|
2:15pm-3:15pm |
Contributed Workshops –
Session III |
|
|
|
Quality
of Life/Patient-Reported Outcomes/Valuation Issues |
|
WW2 |
CONJOINT
ANALYSIS IN REAL TIME: USING STATED-PREFERENCE ESTIMATES TO INFORM
DRUG-DEVELOPMENT DECISION MAKING
Johnson R, Hauber B, Research Triangle Institute, Research
Triangle Park, NC, USA |
|
WW18 |
PATIENT
SATISFACTION WITH MEDICATION: DEFINITION, MEASUREMENT AND INTERPRETATION
ISSUES
Marquis P1, Trudeau E2, Keininger D1, 1Mapi Values, Boston, MA,
USA; 2Mapi Values, Lyon, France
|
|
|
Outcomes Research – Practical Application Issues |
|
WW19
|
MICROSIMULATION MODELING IN PHARMACOECONOMIC ANALYSIS
Thompson D1, Bogard E1, Weinstein MC2, 1Innovus
Research, Inc, Medford, MA, USA; 2Harvard School of Public Health &
Innovus Research, Inc, Boston, MA, USA
|
|
WW20 |
WOULD THE
APPLICATION OF MODERN ECONOMIC THEORY IMPROVE THE PRACTICE OF
PHARMACEUTICAL ECONOMICS?
Kevin M1, Kemp R2, Glass H1, 1University of the Sciences in
Philadelphia, Philadelphia, PA, USA; 2Pharmacia Corporation, Peapack,
NJ, USA
|
|
WW21 |
DESIGNING
AND EVALUATING INTERVENTIONS TO IMPROVE PATIENT COMPLIANCE WITH
PRESCRIBED MEDICATIONS
Benner JS1, Cramer JA2, Rubin D3, 1Epinomics
Research, Inc, Alexandria, VA, USA; 2Yale University School of Medicine,
West Haven, CT, USA; 3Adheris, Inc., Woburn, MA, USA |
|
|
Cost
Study Issues |
|
WW22 |
USE AND
MISUSE OF THE CASE-CONTROL METHODOLOGY IN ECONOMIC ANALYSES
Caro J, Huybrechts K, Caro Research Institute, Concord,
MA, USA
|
|
|
Clinical Study Issues |
|
WW23 |
INTERPETING SUBGROUP ANALYSES IN EPIDEMIOLOGICAL STUDIES FROM A
COST-EFFECTIVENESS PERSPECTIVE: OVERVIEW OF IMPLICATIONS AND POTENTIAL
MISAPPLICATIONS WITH AN INTERACTIVE ILLUSTRATION
Levey AR1, Briggs AH2, Gagnon YM3, 1University of British
Columbia, Vancouver, BC, Canada; 2University of Oxford, Oxford, UK;
3Occam Research & Consulting, Vancouver, BC, Canada
|
|
WW24 |
REGISTRIES: BALANCING CLINICAL AND MARKETING AGENDAS
Gordon MJ, Trotter JP, Ovation Research Group, Highland Park, IL,
USA
|
|
|
|
3:15pm-3:30pm |
Break |
|
Break sponsored by NOVARTIS |
|
|
|
3:30pm-4:30pm |
ISPOR Forums |
|
|
|
Risk Management Special Interest Group
Forum Speakers:
Eva Lydick PhD,
Risk Management Co-Chair and Director of Epidemiology AstraZeneca,
Wilmington, DE, USA and Louis Morris PhD, Risk Management Co-Chair and
President of Louis Morris Associates, Dix Hills, NY, USA
During this forum, the three FDA risk management concept papers will be
discussed.
“FDA Concept Paper: Premarketing Risk Assessment” located at:
http://www.fda.gov/cder/meeting/riskManageI.htm. This concept paper
presents FDA's preliminary thoughts on: important risk assessment
concepts, generation and acquisition of safety data during product
development, analysis and presentation of safety data in an application
for approval.
“FDA Concept Paper: Risk Management Programs” located at:
http://www.fda.gov/cder/meeting/riskManageII.htm. This concept paper
presents FDA's preliminary thoughts on: considerations for initiating
and designing a risk management program, the selection and development
of risk management tools, the evaluation of risk management programs,
the recommended elements of a risk management program submissions.
“FDA
Concept Paper: Risk Assessment of Observational Data: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment”
located at: http://www.fda.gov/cder/meeting/riskManageIII.htm. This
concept paper presents FDA's preliminary thoughts on: important
pharmacovigilance concepts, safety signal identification,
pharmacoepidemiologic assessment and interpretation of safety signals,
the development of pharmacovigilance plans.
|
|
3:30pm-3:35pm |
Managed Care_PBM Special Interest Group
Forum |
| |
Moderators: Dell Mather PharmD, Managed
Care_PBM SIG Co-Chair and Senior Director, Pharmacotherapy Assessment &
Policy, Prime Therapeutics, Eagan, Minnesota, USA and
Ed Hedblom PharmD, Managed Care_PBM SIG
Co-Chair and Global Manager, Health Economics, 3M Medical, St. Paul, MN,
USA
During this forum, the five MC_PBM Working Groups will present their
accomplishments and future plans.
|
|
3:35pm-3:45pm |
Speaker: Peter Neumann ScD, Research Agenda Working Group Chair and Assssociate Professor of Policy & Decision Sciences, Harvard School of
Public Health, Boston, MA, USA
A summary of the proposed supplement for Value in Health, titled Using
Pharmacoeconomics and Outcomes Research in Healthcare Decisions: Where
Are We Going? will be presented.
|
|
3:45pm-3:55pm |
Speaker: Jon
Clouse RPh, MS Education Working Group Chair and Executive Vice
President, Ingenix, Eden Prairie, MN, USA
An overview of the bi-directional educational programs for healthcare
decision-makers and purchasers, as well as pharmacoeconomics and
outcomes researchers will be presented, including a summary of the
pre-meeting symposium: Pharmacoeconomics in a
Managed Care Environment: Opportunities and Challenges.
|
|
3:55pm-4:05pm |
Speaker: Dennis
Raisch RPh, PhD, Research Digest Working Group Chair and
Associate Director, VA Cooperative Studies Program, Clinical Research
Pharmacy, Albuquerque, NM, USA
An update on the ISPOR Website-based Managed Care Outcomes Research
Digest, including research criteria and search terms, will be presented.
|
|
4:05pm-4:15pm |
Speaker:
Barbara Edelman Lewis PhD, MHA, Research Network Working Group
Chair and Director, US Scientific Initiatives & Customer Support, HEOR,
AstraZeneca, Worcester, MA, USA
To encourage research collaboration and networking opportunities, the
Research Network Working Group is developing a survey/questionnaire that
will become part of the ISPOR membership profile. Members will be able
to choose disease, methodology and/or topic categories of interest and
get in touch with other members who share their interest.
|
|
4:15pm-4:25pm |
Speaker: Elinor
CG Chumney PhD, MSc, Pharmacoeconomic & Outcomes Research (PEOR)
Language Working Group Chair and Assistant Professor, Department of
Pharmacy Practice, Medical University of South Carolina, Charleston, SC,
USA
The PE/OR Language Working Group’s goal is to ascertain whether
terminology is an impediment to communication between healthcare
purchasers / providers / decision makers and pharmacoeconomic and
outcomes researchers. Do terms like cost-effectiveness, disease
management and discounting have the same meaning amongst the various
users? They will present
their findings on the 25 sources used.
|
|
4:25pm-4:35pm |
Moderators:
Dell Mather PharmD, Managed Care_PBM SIG Co-Chair and Senior
Director, Pharmacotherapy Assessment & Policy, Prime Therapeutics,
Eagan, Minnesota, USA and Ed Hedblom PharmD,
Managed Care_PBM SIG Co-Chair and Global Manager, Health Economics, 3M
Medical, St. Paul, MN, USA
Closing Remarks
|
| |
Vision 2010 Committee
Forum
Forum sponsored by MERCK |
| |
Co-Moderators:
Marc Berger, MD, Vice President, Outcomes Research & Management
Merck & Company, Inc., West Point, PA, USA and
Gerry Oster PhD, Vice President, PAI, Brookline, MA, USA
Panelists: Bryan Luce, PhD,MBA,
Senior Research Leader & CEO, MEDTAP International, Bethesda, MD, USA
Jon Clouse, RPh, MS, Executive Vice
President, Ingenix, Eden Prairie, MN, USA
Karen Rascati, RPh, PhD, Professor,
University of Texas, Phar. Pharmacy Admin, Austin, TX, USA
Ron Akehurst, BS, Dean of School of Health
& Related Research, ScHARR, The University of Sheffield, Sheffield, UK
Isao Kamae, MD, DrPh, Professor of Health
Sciences and Informatics, Graduate School of Medicine, Kobe University,
Research Center for Urban Safety & Security (RCUSS), Kobe, JAPAN
The mission of the ISPOR Vision 2010 Committee is to provide
recommendations to the President and the Board of Directors regarding
the long-term evolution and growth of the organization, and to consider
strategies to enhance its effectiveness. Members of the ISPOR Vision
2010 Committee will discuss a number of issues including:
• Who are we? • Who do we want to be?
• How do we become it? • Where are we?
• Where do we want to go? • How should we get there?
|
| 4:30pm-5:30pm |
Quality of Life Special
Interest Group: Analysis & Interpretation Working Group Presentation
|
| |
Moderator:
Michael Friedman PhD, Analysis & Interpretation Working Group
Chair and Director of Biostatistics, Purdue Pharma, Stamford, CT, USA
Panelists: QOL SIG Analysis & Interpretation Working Group Core
Members
Meryl Brod PhD, President, The Brod Group,
Mill Valley, CA, USA
Don Bushnell MA, Associate Director, Health
Research Associates, Mountlake Terrace, WA, USA
William B. Carter PhD, formerly Professor,
School of Public Health and Community Medicine, University of Washington
and Associate Director, Pharmacoeconomics, Amgen, Moorpark, CA, USA
Joyce Cramer, Associate Research Scientist,
Yale University Medical School, Westhaven, CT, USA
Luis Prieto PhD, Health Outcomes Research
Unit, Lilly, S.A., Madrid, Spain
Kathleen W. Wyrwich PhD, Assistant
Professor of Research Methodology & Health Services Research, Saint
Louis University, Saint Louis, MO, USA
The Analysis & Interpretation Working Group Core Members will present
their findings from a recent literature review on methodological
articles focusing on the clinical significance of QOL measures and other
patient-related outcomes. They will also discuss the most key and
controversial issues in this area and their plans for an ISPOR
Website-based digest of articles on issues such as: best practices in
health-related QOL assessment, common issues on interpretation, ways to
handle missing data and instrument developers’ missing data
requirements.
|
|
4:30pm-5:30pm |
ISPOR Business Meeting
|
|
4:30-4:35 |
CALL TO
ORDER: Peter G. Davey MD, FRCP, 2002-2003
ISPOR President
|
|
4:35-4:40 |
EXECUTIVE
DIRECTOR'S REPORT: Marilyn Dix Smith PhD,
ISPOR Executive Director
|
|
4:40-4:45 |
TREASURER'S REPORT: Jean Paul Gagnon PhD,
ISPOR Treasurer
|
|
4:45-4:50 |
AUDIT
REPORT: Peter Fullerton PhD, Chair, ISPOR Audit Committee
|
|
4:50-4:55 |
VALUE IN
HEALTH EDITOR-IN-CHIEF REPORT: Josephine Mauskopf PhD, Value in Health
Editor-in-Chief
|
|
4:55-5:00 |
ISPOR
CONNECTIONS EDITOR-IN-CHIEF REPORT: Steven E. Marx PharmD, MS, ISPOR
CONNECETIONS Editor-in-chief
|
|
5:00-5:20 |
ISPOR
COMMITTEE REPORTS
- Education Committee Report: Karen
Rascati PhD, Education Committee Chair
- Health Science Report: John Hutton,
Health Science Committee Report
- Strategic Outreach Committee Report:
Michael Drummond PhD, Strategic Outreach Committee Chair
- Vision 2010 Committee Report: Marc
Berger MD and Gerry Oster PhD, ISPOR Vision 2010 Committee Co-chairs
|
|
5:20-5:25 |
INSTALLATION OF THE 2003-2004 ISPOR OFFICERS: Peter G. Davey MD, FRCP,
2002-2003 ISPOR President
|
|
5:25-5:30 |
NEW
BUSINESS: Peter G. Davey MD, FRCP, 2002-2003 ISPOR President
|
|
5:30 |
MEETING
ADJOURNMENT: Peter G. Davey MD, FRCP, 2002-2003 ISPOR President
|
|
5:00pm-7:00pm |
Exhibitors’ Closing
Reception & Contributed Poster Presentations (Session II) |
|
|
|
7:00pm-9:00pm |
ISPOR Connections Editorial
Board Dinner Meeting (Private) |
|
|
|
